During the recently celebrated 24th Biennial Congress of the European Association for Cancer Research (EACR), 09 – 12 July, Manchester UK, ecancer caught up with VHIO´s Joan Seoane, Director of Translational Research, to discuss multidisciplinary research aimed at better detecting cancer mutations, tracking the evolution of disease, as well as predicting response to therapy.
More specifically, Joan underlines the potential of cerebrospinal fluid (CSF) as liquid biopsy for the early diagnosis, prognosis, therapeutic management, and the ´real time´ tracking of brain cancer in a less invasive manner compared to traditional procedures.
To access and view the video please click here.
For more background information surrounding this pioneering approach and promising new direction in the study of brain cancer and metastases please see the following VHIO news published last November:
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Con la incorporación de Sanitas y las suscripciones ya firmadas con a...
